[en] Thiazolidinediones (TZDs) are used as insulin sensitizers in the treatment of type 2 diabetes, but are associated with an increased risk of congestive heart failure (CHF). The odds ratio of ICC was 1.43 (pioglitazone vs placebo) in diabetic patients with high cardiovascular risk in the PROactive trial while it averaged 1.22 (rosiglitazone vs metformin) and 2.20 (rosiglitazone vs metformin) in the ADOPT study. In the interim analysis of the ongoing RECORD trial, the odds ratio averaged 2.15 (rosiglitazone vs metformin or sulfonylureas). In four real life registries, the relative risk of CHF with TZDs varied between 1.06 and 1.76 (between 1.10 and 1.44 combined with insulin) as compared to a treatment without TZDs. Such higher CHF risk should be appreciated according to the potential benefits of glitazones in the management of type 2 diabetes.
De Flines, Jenny ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Glitazones et insuffisance cardiaque: resultats des etudes PROactive, ADOPT, DREAM et RECORD.
Alternative titles :
[en] Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials
* De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités é tiopathogéniques et thérapeutiques. Rev Med Suisse 2006;2:1893-900.
** Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: Critical appraisal for the clinician. Circulation 2003;107:1350-4.
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
Lindenfeld J, Masoudi FA. Fluid retention with thiazolidinediones. Does the mechanism influence the outcome ? J Am Coll Cardiol 2007;49:1705-7.
** Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
** Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
** The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-105.
Yki-Járvinen H. The PROactive study: Some answers, many questions. Lancet 2005;366:1241-2.
Ryden L, Thrainsdottir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet 2007;369:189-90.
Erdmann E, Dormandy JA, Charbonnel B et al, on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 2007;49:1772-80.
Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38: 865-73.
Delea TE, Edetsberg JS, Hagiwara M, Oster G, Philips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study. Diabetes Care 2003;26:2983-9.
Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing anti hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9.
Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;11:583-90.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006; Issue 4:CD006060.
* Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2006;76:279-89.
De Flines J, Scheen AJ. Pioglitazone, oedema and congestive heart failure: A meta-analysis of randomised controlled trials (abstract). Diabetologia 2007;50 (Suppl. 1): in press.
Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6.
Scheen AJ. Combined thiazolidinedione-insulin therapy. Should we be concerned about safety? Drug Safety 2004;27:841-56.
Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-8.
Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis. Diabetes Care 2007;30:384-8.
* Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
Psaty BM, Furberg CD. Editorial. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005;48:1726-35.
* Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
Nathan DM. Rosiglitazone and cardiotoxicity - Weighing the evidence. N Engl J Med 2007;357:64-6.